Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 151 - 171 av 171 resultater
Tid
Selskap
Tittel
Sektor
Kategori
17 Dec 2021
17:45 CET
TRANSGENE
Transgene Announces Investor Meetings for January 2022
20103010 Biotechnology
Meetings / events
15 Dec 2021
07:30 CET
TRANSGENE
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
20103010 Biotechnology
Alliances and agreements
15 Dec 2021
07:30 CET
TRANSGENE
Transgene annonce une levée d’option de licence par AstraZeneca pour un virus oncolytique issu de sa plateforme Invir.IO™
20103010 Biotechnology
Alliances and agreements
22 Nov 2021
17:45 CET
TRANSGENE
Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
20103010 Biotechnology
Products and services
22 Nov 2021
17:45 CET
TRANSGENE
Transgene et NEC annoncent des premiers résultats positifs des essais de Phase I de TG4050, un vaccin thérapeutique individualisé innovant contre le cancer
20103010 Biotechnology
Products and services
09 Nov 2021
14:00 CET
TRANSGENE
Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021
20103010 Biotechnology
New
09 Nov 2021
14:00 CET
TRANSGENE
Transgene et BioInvent présentent des données précliniques soulignant la forte activité antitumorale du virus oncolytique BT-001 au SITC 2021
20103010 Biotechnology
New
04 Nov 2021
17:45 CET
TRANSGENE
Transgene Reports Business Update and Q3 2021 Financial Position
20103010 Biotechnology
Income
04 Nov 2021
17:45 CET
TRANSGENE
Transgene publie sa situation financière et fait un point sur son activité au troisième trimestre 2021
20103010 Biotechnology
Income
01 Oct 2021
15:00 CEST
TRANSGENE
Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021
20103010 Biotechnology
Products and services
01 Oct 2021
15:00 CEST
TRANSGENE
Transgene et BioInvent présenteront des données précliniques sur le virus oncolytique BT-001 au SITC 2021
20103010 Biotechnology
Products and services
22 Sep 2021
17:45 CEST
TRANSGENE
Progression des deux plateformes innovantes de Transgene et visibilité financière étendue à fin 2023
20103010 Biotechnology
Other financial transaction
22 Sep 2021
17:45 CEST
TRANSGENE
Mise à disposition du Rapport Financier Semestriel au 30 juin 2021
20103010 Biotechnology
Income
22 Sep 2021
17:45 CEST
TRANSGENE
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
20103010 Biotechnology
Other financial transaction
22 Sep 2021
17:45 CEST
TRANSGENE
Availability of Transgene’s Half-Year Financial Report as of June 30, 2021
20103010 Biotechnology
Income
16 Sep 2021
08:30 CEST
TRANSGENE
Transgene présente des données de Phase I confirmant le potentiel du virus oncolytique TG6002
20103010 Biotechnology
Other subject
16 Sep 2021
08:30 CEST
TRANSGENE
Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
20103010 Biotechnology
Other subject
13 Sep 2021
08:00 CEST
TRANSGENE
Transgene Announces Upcoming Investor Meetings
20103010 Biotechnology
Meetings / events
13 Sep 2021
08:00 CEST
TRANSGENE
Transgene annonce ses prochaines rencontres avec les investisseurs
20103010 Biotechnology
Meetings / events
01 Sep 2021
17:45 CEST
TRANSGENE
Transgene Participates in New Cancer Research Consortium
20103010 Biotechnology
Other subject
01 Sep 2021
17:45 CEST
TRANSGENE
Transgene participe à un nouveau consortium de recherche contre le cancer
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva